Dr. Kelly is a scientific leader with both Pharma and Biotech experience and a track record of delivering high quality compounds into advanced clinical studies. He is well versed in chemistry, disease biology and the enabling technologies needed for innovative and efficient drug discovery from lead identification through clinical development. In particular, he has extensive hands on drug discovery and development experience in Inflammation, Cardiovascular and CNS disorders. Dr. Kelly has served as a director of Cardax, Inc. since June 2014.
Dr. Kelly is currently the President and Chief Executive Officer of CoMentis, Inc. and a founder of Kelly Pharma Research Consulting, LLC. Between 1990 and 2009, Dr. Kelly served in various scientific and executive positions at Boehringer Ingelheim, where after a successful early career developing LFA-1 antagonists, he led its US-based medicinal chemistry department comprising145 scientists in the high throughput screening, computational chemistry, structural biology, combinatorial chemistry and medicinal chemistry groups.
Dr. Kelly holds a B.S. degree in Chemistry at Rensselaer Polytechnic Institute (1982) and a Ph.D. degree in Chemistry at the University of Texas at Austin (1988). He completed postdoctoral work in natural products synthesis at Yale University (1988-1990) and holds an MBA from New York University, Stern School of Business (1998). Dr. Kelly is the co-author of over 25 scientific publications and serves on the College of Natural Sciences Advisory Council for the University of Texas.